In this issue:
Induction risankizumab for CD
Maintenance risankizumab for moderately to severely active CD
ARFID is prevalent in IBD
Serious infections after in utero thiopurine or anti-TNF exposure
Peripartum biologic exposure does not impact post partum wound healing
Impact of NAFLD on hospitalisation outcomes in IBD
Ustekinumab for CD ± autoimmune skin disease
High psychological resilience associated with decreased anxiety in IBD
Colorectal strictures in IBD do not independently predict colorectal neoplasia
Infection risk lower with vedolizumab than anti-TNF agents in older adults
Please login below to download this issue (PDF)